

<b>INFORMATION DISCLOSURE STATEMENT</b>	<i>Complete If known</i>	
	Application Number:	10/671,376
	Filing Date:	September 25, 2003
	First Named Inventor:	Janina Baranowska-Kortylewicz, et al.
	Group Art Unit:	1632
	Examiner Name:	Not Yet Assigned
SHEET 1 OF 2		Attorney Docket Number: 0685-UNMC.63184

UNITED STATES PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
CK HO	A1	5,096,694	03/17/1992	Quivy et al.
CK HO	A2	5,468,853	11/21/1993	Baranowska-Kortylewicz

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
CK HO	B1	WO 90/03799	WO	04-19-1990	Centocor, Inc.

OTHER PRIOR ART - NON-PATENT DOCUMENTS		
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
CK HO	C1	BONASERA, T.A. et al. "Preclinical Evaluation of Fluorine-18-Labeled Androgen Receptor Ligands in Baboons"; Journal of Nuclear Medicine, <b>37(6)</b> : 1009-1015 (1996)
	C2	CHOE, Y.S. et al. "Synthesis of 11 $\beta$ -[ <sup>18</sup> F]Fluro-5 $\alpha$ -dihydrotestosterone and 11 $\beta$ -[ <sup>18</sup> F]Fluro-19-nor-5 $\alpha$ -dihydrotestosterone: Preparation via Halofluorination-Reduction, Receptor Binding, and Tissue Distribution"; Journal of Medicinal Chemistry, <b>38(5)</b> : 816-825 (1995)
	C3	DOWNER, J.B. et al. "Comparison of animal models for the evaluation of radiolabeled androgens"; Nuclear Medicine and Biology, <b>28(6)</b> : 613-626 (2001)
	C4	HOYTE, R.M. et al. "7 $\alpha$ -Methyl-17 $\alpha$ -(E-2'-[ <sup>125</sup> I]iodovinyl)-19-nortestosterone: a new radioligand for the detection of androgen receptor"; Steroids, <b>58(1)</b> : 13-23 (1993)
	C5	LABAREE, D.C. et al. "7 $\alpha$ -Iodine-125-Iodo-5 $\alpha$ -Dihydrotestosterone: A Radiolabeled Ligand for the Androgen Receptor"; Journal of Nuclear Medicine, <b>38(3)</b> : 402-409 (1997)
	C6	LARA, P.N. et al. "Treatment Options in Androgen-Independent Prostate Cancer"; Cancer Investigation, <b>17(2)</b> : 137-144 (1999)
	C7	LIU, A. et al. "Fluorine-18-Labeled Androgens: Radiochemical Synthesis and Tissue Distribution Studies on Six Fluorine-Substituted Androgens, Potential Imaging Agents for Prostatic Cancer"; Journal of Nuclear Medicine, <b>33(5)</b> : 724-734 (1992)
CK VHO	C8	SALMAN, M. et al. "A Potential Radioiodinated Ligand for Androgen Receptor: 7 $\alpha$ -Methyl-17 $\alpha$ -(2'-(E)-iodovinyl)-19-nortestosterone"; Journal of Medicinal Chemistry, <b>34(3)</b> : 1019-1024 (1991)

EXAMINER'S SIGNATURE	<i>[Signature]</i>	DATE CONSIDERED	6-10-05
----------------------	--------------------	-----------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Complete if known</b>	
	Application Number:	10/671,376
	Filing Date:	September 25, 2003
	First Named Inventor:	Janina Baranowska-Kortylewicz, et al.
	Group Art Unit:	1632
	Examiner Name:	Not Yet Assigned
SHEET 2 OF 2		Attorney Docket Number: 0685-UNMC.63184

EIL HLO [Handwritten line] [Handwritten line] [Handwritten line] [Handwritten line] [Handwritten line] [Handwritten line] [Handwritten line] [Handwritten line] [Handwritten line]	C9	VAN DEN BOS, J.C., et al. "New Iodinated Progestins as Potential Ligands for Progesterone Receptor Imaging in Breast Cancer. Part 1: Synthesis and <i>in Vitro</i> Pharmacological Characterization"; Nuclear Medicine & Biology, <b>25(8)</b> : 781-789 (1998)
	C10	WARTERS, R.L. et al. "Radionuclide Toxicity in Cultured Mammalian Cells: Elucidation of the Primary Site of Radiation Damage"; Current Topics in Radiation Research Quarterly, <b>12</b> : 389-407 (1997)
	C11	MAKRIGIORGOS, G.M. et al. "Radiotoxicity of 5-[ <sup>125</sup> I]Iodo-2'-deoxyuridine in V79 Cells: A Comparison with 5-[ <sup>125</sup> I]Iodo-2'-deoxyuridine"; Radiation Research, <b>118</b> : 532 (1989)
	C12	BARANOWSKA-KORTYLEWICZ, J. et al. "5-[ <sup>125</sup> I]Iodo-2'-Deoxyuridine in the Radiotherapy of an Early Ascites Tumor Model"; Int. J. Radiat. Oncol. Biol. Phys., <b>21</b> : 1541-1551 (1991)
	C13	KYRIAKOS, R.J. et al. "The Fate of Antibodies Bound to the Surface of Tumor Cells <i>in Vitro</i> "; Cancer Research, <b>52</b> : 835-842 (1992)
	C14	BRYAN, R.M. et al. "Androgen Receptors in Breast Cancer"; Cancer, <b>54</b> : 2436-2440 (1984)
	C15	LEA, O.A. et al. "Improved Measurement of Androgen Receptors in Human Breast Cancer"; Cancer Research, <b>49</b> : 7162-7167 (1989)
	C16	SOREIDE, J.A. et al. "Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment"; European Journal of Surgical Oncology, <b>18</b> : 112-118 (1992)
	C17	POULIN, R. et al. "Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line"; Breast Cancer Research and Treatment, <b>12</b> : 213-225 (1988)
	C18	INGLE, J.N. et al. "Combination Hormonal Therapy With Tamoxifen Plus Fluoxymesterone Versus Tamoxifen Alone in Postmenopausal Women With Metastatic Breast Cancer"; Cancer, <b>67</b> : 886-891 (1991)
[Handwritten mark]	C19	MARIANI, G. et al. "Tumor Targeting Potential and Metabolism of 5-[ <sup>125</sup> I]Iodo-2'-Deoxyuridine Injected Intratumorally in Patients with Breast Cancer"; Ann N Y Acad. Sci., <b>698</b> : 204-211 (1993)

EXAMINER'S SIGNATURE		DATE CONSIDERED	6-10-05
-------------------------	---	--------------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.